GlycoMimetics (CBIO) Stock Price, News & Analysis

Company Overview

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Key Stats

• Today's Range: $11.06 to $15.81
• 50-Day Range: N/A
• 52-Week Range: $11.06 to $63.00
• Volume: 97,196 shs
• Average Volume: 51,804 shs
• Market Capitalization: $9.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

GlycoMimetics Stock Analysis - MarketRank™

GlycoMimetics scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

GlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GlycoMimetics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GlycoMimetics are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GlycoMimetics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GlycoMimetics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GlycoMimetics has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GlycoMimetics does not currently pay a dividend.

Dividend Growth

GlycoMimetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -0.84

Short Interest

There is no current short interest data available for CBIO.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.10

News Sentiment

GlycoMimetics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for GlycoMimetics this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for CBIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of GlycoMimetics is held by insiders.

Percentage Held by Institutions

75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CBIO Stock Analysis - Frequently Asked Questions

How have CBIO shares performed this year?

GlycoMimetics' stock was trading at $15.7950 at the beginning of 2025. Since then, CBIO stock has decreased by 7.4% and is now trading at $14.62.
View the best growth stocks for 2025 here.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:CBIO) issued its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($7.00).

When did GlycoMimetics' stock split?

Shares of GlycoMimetics reverse split before market open on Monday, June 16th 2025. The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of GlycoMimetics?

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 6/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBIO
• Previous Symbol: NASDAQ:CBIO
• CIK: 1253689
• Web: www.crescentbiopharma.com
• Phone: 617-465-0586
• Fax: 336-480-2107
• Employees: 26
• Year Founded: 2003

Price Target and Rating

• Average Stock Price Target: $22.00
• High Stock Price Target: $22.00
• Low Stock Price Target: $22.00
• Potential Upside/Downside: +50.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($46.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.88 million
• Net Margins: N/A
• Pretax Margin: -397,340.00%
• Return on Equity: -293.92%
• Return on Assets: -206.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.29
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 950.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.24 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 650,000
• Free Float: 619,000
• Market Cap: $9.50 million
• Optionable: No Data
• Beta: 1.62